Seattle Genetics Company Profile (NASDAQ:SGEN)

About Seattle Genetics (NASDAQ:SGEN)

Seattle Genetics logoSeattle Genetics, Inc. is a biotechnology company focused on the development and commercialization of therapies for the treatment of cancer. The Company is engaged in the development and sale of pharmaceutical products on its own behalf or in collaboration with others. The Company's marketed product ADCETRIS, or brentuximab vedotin, is an antibody-drug conjugate (ADC). In addition to ADCETRIS, the Company's pipeline includes other clinical-stage ADC programs, such as ASG-22ME, SGN-LIV1A, SGN-CD19A, SGN-CD19B, SGN-CD123A, SGN-352A, and ASG-15ME, as well as two immuno-oncology agents, SEA-CD40, which is based on its sugar-engineered antibody (SEA) technology, and SGN-2FF, which is a small molecule. It also has multiple preclinical and research-stage programs that employ its technologies, including SGN-CD48A and a preclinical ADC. ADCETRIS is an ADC comprising an anti-CD30 monoclonal antibody attached by a protease-cleavable linker to a microtubule disrupting agent.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: Biotechnology
  • Symbol: NASDAQ:SGEN
  • CUSIP: 81257810
  • Web:
  • Market Cap: $9.63 billion
  • Outstanding Shares: 142,716,000
Average Prices:
  • 50 Day Moving Avg: $64.79
  • 200 Day Moving Avg: $63.68
  • 52 Week Range: $35.93 - $75.36
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -60.77
  • P/E Growth: -0.02
Sales & Book Value:
  • Annual Revenue: $416.12 million
  • Price / Sales: 23.13
  • Book Value: $4.23 per share
  • Price / Book: 15.95
  • EBIDTA: ($162,430,000.00)
  • Net Margins: -33.51%
  • Return on Equity: -20.86%
  • Return on Assets: -16.21%
  • Current Ratio: 5.92%
  • Quick Ratio: 5.35%
  • Average Volume: 696,110 shs.
  • Beta: 2.25
  • Short Ratio: 11.71

Frequently Asked Questions for Seattle Genetics (NASDAQ:SGEN)

What is Seattle Genetics' stock symbol?

Seattle Genetics trades on the NASDAQ under the ticker symbol "SGEN."

How were Seattle Genetics' earnings last quarter?

Seattle Genetics, Inc. (NASDAQ:SGEN) posted its quarterly earnings results on Thursday, April, 27th. The company reported ($0.42) EPS for the quarter, missing the Zacks' consensus estimate of ($0.41) by $0.01. The company earned $109.10 million during the quarter, compared to analyst estimates of $103.23 million. Seattle Genetics had a negative net margin of 33.51% and a negative return on equity of 20.86%. The firm's revenue for the quarter was down 1.9% compared to the same quarter last year. During the same period last year, the firm earned ($0.15) EPS. View Seattle Genetics' Earnings History.

When will Seattle Genetics make its next earnings announcement?

Seattle Genetics is scheduled to release their next quarterly earnings announcement on Monday, July, 24th 2017. View Earnings Estimates for Seattle Genetics.

Where is Seattle Genetics' stock going? Where will Seattle Genetics' stock price be in 2017?

17 equities research analysts have issued 1 year price objectives for Seattle Genetics' shares. Their forecasts range from $38.00 to $80.00. On average, they expect Seattle Genetics' stock price to reach $59.58 in the next year. View Analyst Ratings for Seattle Genetics.

What are analysts saying about Seattle Genetics stock?

Here are some recent quotes from research analysts about Seattle Genetics stock:

  • 1. According to Zacks Investment Research, "Seattle Genetics missed bottom-line expectations in the first quarter of 2017 but sales came in ahead of estimates. With the recent llabel expansion of Keytruda in the lymphoma indication, investor focus will likely remain on Adcetris sales in the upcoming quarters. A decline in Adcetris sales will hurt the company's top line. Though, the company has a number of candidates in its pipeline, most of them are in early stages of development. Although the clinical hold on several early-stage trials of vadastuximab talirine in acute myeloid leukemia (AML) was lifted in Mar 2017, Seattle Genetics has a long way to go before the candidate comes close to commercialization. However, the company’s collaboration agreement with Takeda for the global development and commercialization of Adcetris is encouraging. Also, collaborations with companies like AbbVie, Bayer, Roche and Pfizer provide it with funds in the form of upfront, milestone and other payments." (5/2/2017)
  • 2. Cann analysts commented, "Seattle Genetics released Q1 2017 results today. Loss per share of $0.42 was 8.4% higher than our estimated $0.39. This was the result of operating expense being 4.8% higher than estimated and other net income expense of $1.2 million. This was partially offset by higher than estimated revenue, which exceeded our estimated $104.4 million by 4.5% due to higher than estimated royalty revenue. The most important metric for the quarter, Adcetris sales, was in line with our estimate at $70.3 million. Our outlook for Seattle Genetics remains basically unchanged with revenue and EPS estimates unchanged for 2018-2021 and with 2017 EPS decreased by $0.01." (4/27/2017)
  • 3. Cantor Fitzgerald analysts commented, "The FDA has lifted the clinical hold placed on vadastuximab talirine, which was initiated in late December and primarily affected earlier-stage studies as the Phase III CASCADE trial and a Phase I/II for frontline high risk MDS were." (3/6/2017)
  • 4. HC Wainwright analysts commented, "CVT-301 data may be good start to 2017. ACOR released top-line data from the pivotal study of CVT-301 (pulmonary inhaled levodopa) this morning. The company reported that the 80mg dose (but not the 60mg dose) produced a statistically significant (p=0.009) improvement in the Unified Parkinson’s Diseases Rating Scale Part-3 (UPDRS III) with a placebo-adjusted treatment effect of -3.92 (-9.83 score for CVT-301)." (2/10/2017)
  • 5. Cowen and Company analysts commented, "SGEN presented updated Phase I data for SGN-LIV1A in mBC this weekend at SABCS." (12/12/2016)

Who are some of Seattle Genetics' key competitors?

Who owns Seattle Genetics stock?

Seattle Genetics' stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include BAKER BROS. ADVISORS LP (32.20%), Baillie Gifford & Co. (11.37%), Primecap Management Co. CA (9.25%), FMR LLC (7.14%), Vanguard Group Inc. (5.17%) and BlackRock Inc. (5.10%). Company insiders that own Seattle Genetics stock include Clay B Siegall, Darren S Cline, David W Gryska, Eric Dobmeier, Felix Baker, John A Orwin, Jonathan G Drachman, Marc E Lippman, Todd E Simpson and Vaughn B Himes. View Institutional Ownership Trends for Seattle Genetics.

Who sold Seattle Genetics stock? Who is selling Seattle Genetics stock?

Seattle Genetics' stock was sold by a variety of institutional investors in the last quarter, including FMR LLC, Artisan Partners Limited Partnership, Redmile Group LLC, Baillie Gifford & Co., First Trust Advisors LP, Columbia Wanger Asset Management LLC, Lagoda Investment Management L.P. and UBS Group AG. Company insiders that have sold Seattle Genetics stock in the last year include Clay B Siegall, Darren S Cline, Eric Dobmeier, Jonathan G Drachman, Marc E Lippman and Vaughn B Himes. View Insider Buying and Selling for Seattle Genetics.

Who bought Seattle Genetics stock? Who is buying Seattle Genetics stock?

Seattle Genetics' stock was purchased by a variety of institutional investors in the last quarter, including BlackRock Inc., Point72 Asset Management L.P., Pictet Asset Management Ltd., Janus Capital Management LLC, State Street Corp, Vanguard Group Inc., Wells Fargo & Company MN and Westfield Capital Management Co. LP. Company insiders that have bought Seattle Genetics stock in the last two years include Felix Baker and John A Orwin. View Insider Buying and Selling for Seattle Genetics.

How do I buy Seattle Genetics stock?

Shares of Seattle Genetics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Seattle Genetics stock cost?

One share of Seattle Genetics stock can currently be purchased for approximately $67.45.

Analyst Ratings

Consensus Ratings for Seattle Genetics (NASDAQ:SGEN) (?)
Ratings Breakdown: 3 Sell Ratings, 10 Hold Ratings, 4 Buy Ratings
Consensus Rating:Hold (Score: 2.06)
Consensus Price Target: $59.58 (11.66% downside)

Analysts' Ratings History for Seattle Genetics (NASDAQ:SGEN)
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
4/28/2017HC WainwrightBoost Price TargetBuy$65.00 -> $75.00LowView Rating Details
4/27/2017CannReiterated RatingHoldLowView Rating Details
4/7/2017Leerink SwannBoost Price TargetOutperform$70.00 -> $74.00MediumView Rating Details
3/16/2017CIBCInitiated CoverageMarket Perform -> Market PerformLowView Rating Details
3/16/2017Oppenheimer Holdings Inc.Initiated CoverageMarket PerformLowView Rating Details
3/6/2017Cantor FitzgeraldReiterated RatingHold$43.00N/AView Rating Details
2/16/2017Bank of America CorpDowngradeNeutral -> UnderperformN/AView Rating Details
2/13/2017Credit Suisse Group AGBoost Price TargetNeutral$62.00 -> $66.00N/AView Rating Details
1/5/2017Royal Bank of CanadaSet Price TargetBuy$80.00N/AView Rating Details
1/5/2017Maxim GroupReiterated RatingReduceN/AView Rating Details
12/27/2016Needham & Company LLCReiterated RatingHold$72.00N/AView Rating Details
12/12/2016Cowen and CompanyReiterated RatingHold$47.00N/AView Rating Details
11/29/2016Barclays PLCDowngradeOverweight -> Equal Weight$53.00 -> $70.00N/AView Rating Details
10/31/2016JPMorgan Chase & Co.Reiterated RatingHold$43.00N/AView Rating Details
9/16/2016Goldman Sachs Group IncDowngradeNeutral -> SellN/AView Rating Details
9/7/2016Morgan StanleyInitiated CoverageOverweight$60.00N/AView Rating Details
7/27/2016SunTrust Banks, Inc.Boost Price TargetNeutral$34.00 -> $38.00N/AView Rating Details
2/10/2016Piper Jaffray CompaniesLower Price TargetNeutral$44.00 -> $33.00N/AView Rating Details
8/25/2015William BlairReiterated RatingBuyN/AView Rating Details
(Data available from 5/25/2015 forward)


Earnings History for Seattle Genetics (NASDAQ:SGEN)
Earnings by Quarter for Seattle Genetics (NASDAQ:SGEN)
Earnings History by Quarter for Seattle Genetics (NASDAQ:SGEN)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
4/27/2017Q1 2017($0.41)($0.42)$103.23 million$109.10 millionViewN/AView Earnings Details
2/9/2017Q416($0.34)($0.39)$106.49 million$105.30 millionViewListenView Earnings Details
10/27/2016Q316($0.29)($0.23)$4.34 million$106.30 millionViewListenView Earnings Details
7/26/2016Q216($0.32)($0.23)$94.56 million$95.40 millionViewListenView Earnings Details
4/28/2016Q116($0.09)($0.15)$116.49 million$111.15 millionViewListenView Earnings Details
2/9/2016Q415($0.20)($0.18)$88.00 million$93.50 millionViewN/AView Earnings Details
10/29/2015Q315($0.20)($0.21)$82.35 million$84.10 millionViewListenView Earnings Details
7/30/2015Q215($0.26)($0.38)$78.21 million$77.10 millionViewListenView Earnings Details
4/30/2015Q1($0.19)($0.17)$74.57 million$82.20 millionViewListenView Earnings Details
2/10/2015Q414($0.25)($0.22)$68.34 million$74.30 millionViewListenView Earnings Details
10/30/2014Q314($0.24)($0.13)$66.90 million$75.80 millionViewListenView Earnings Details
7/31/2014Q214($0.23)($0.14)$65.04 million$68.30 millionViewListenView Earnings Details
5/1/2014Q114($0.21)($0.13)$64.62 million$68.30 millionViewListenView Earnings Details
2/11/2014Q413($0.24)($0.13)$59.50 million$67.40 millionViewListenView Earnings Details
11/5/2013Q313($0.22)($0.19)$57.79 million$71.00 millionViewListenView Earnings Details
7/31/2013Q2 2013($0.20)($0.06)$58.12 million$773.60 millionViewListenView Earnings Details
5/7/2013Q1 2013($0.19)($0.14)$53.72 million$57.32 millionViewListenView Earnings Details
2/12/2013Q4 2012($0.10)($0.09)$57.21 million$63.90 millionViewListenView Earnings Details
11/7/2012Q312($0.14)($0.12)$52.79 million$49.83 millionViewN/AView Earnings Details
8/8/2012($0.15)($0.15)ViewN/AView Earnings Details
5/8/2012($0.11)($0.11)ViewN/AView Earnings Details
2/13/2012($0.31)($0.24)ViewN/AView Earnings Details
11/3/2011($0.46)($0.35)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Seattle Genetics (NASDAQ:SGEN)
2017 EPS Consensus Estimate: ($1.47)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20171($0.39)($0.39)($0.39)
Q2 20172($0.39)($0.28)($0.34)
Q3 20172($0.42)($0.26)($0.34)
Q4 20172($0.57)($0.23)($0.40)
(Data provided by Zacks Investment Research)


Dividend History for Seattle Genetics (NASDAQ:SGEN)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading and Institutional Ownership History for Seattle Genetics (NASDAQ:SGEN)
Insider Ownership Percentage: 33.30%
Institutional Ownership Percentage: 98.43%
Insider Trades by Quarter for Seattle Genetics (NASDAQ:SGEN)
Institutional Ownership by Quarter for Seattle Genetics (NASDAQ:SGEN)
Insider Trades by Quarter for Seattle Genetics (NASDAQ:SGEN)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
4/5/2017Clay B SiegallInsiderSell14,465$62.99$911,150.35View SEC Filing  
3/31/2017Vaughn B HimesInsiderSell10,000$62.75$627,500.00View SEC Filing  
3/6/2017Clay B SiegallCEOSell14,465$68.04$984,198.60View SEC Filing  
2/6/2017Clay B SiegallInsiderSell14,465$61.54$890,176.10View SEC Filing  
1/6/2017Clay B. SiegallInsiderSell14,465$57.89$837,378.85View SEC Filing  
12/13/2016Darren S. ClineEVPSell10,000$63.38$633,800.00View SEC Filing  
12/8/2016Eric DobmeierCOOSell12,500$65.92$824,000.00View SEC Filing  
12/7/2016Vaughn B. HimesInsiderSell30,000$65.32$1,959,600.00View SEC Filing  
11/8/2016Felix BakerDirectorBuy382,500$59.36$22,705,200.00View SEC Filing  
11/7/2016Clay B. SiegallCEOSell14,465$58.43$845,189.95View SEC Filing  
11/7/2016Marc E. LippmanDirectorSell1,000$57.75$57,750.00View SEC Filing  
11/3/2016Felix BakerDirectorBuy1,030,629$56.13$57,849,205.77View SEC Filing  
11/1/2016Jonathan G. DrachmanCMOSell3,418$51.74$176,847.32View SEC Filing  
10/6/2016Clay B. SiegallInsiderSell14,465$54.41$787,040.65View SEC Filing  
9/22/2016Jonathan G DrachmanCMOSell2,249$56.75$127,630.75View SEC Filing  
9/14/2016Eric DobmeierCOOSell22,918$54.04$1,238,488.72View SEC Filing  
9/13/2016Felix BakerDirectorBuy447,311$50.71$22,683,140.81View SEC Filing  
9/8/2016Clay B. SiegallInsiderSell31,269$50.08$1,565,951.52View SEC Filing  
9/8/2016Felix BakerDirectorBuy414,016$48.43$20,050,794.88View SEC Filing  
8/23/2016Eric DobmeierCOOSell12,589$48.00$604,272.00View SEC Filing  
8/22/2016Clay B. SiegallInsiderSell23,381$46.59$1,089,320.79View SEC Filing  
8/22/2016Eric DobmeierCOOSell5,411$46.59$252,098.49View SEC Filing  
8/22/2016Vaughn B. HimesEVPSell3,991$46.59$185,940.69View SEC Filing  
8/8/2016Clay B. SiegallInsiderSell11,660$47.19$550,235.40View SEC Filing  
7/27/2016Clay B. SiegallInsiderSell4,042$45.20$182,698.40View SEC Filing  
7/6/2016Clay B. SiegallCEOSell7,618$40.56$308,986.08View SEC Filing  
6/6/2016Clay B SiegallCEOSell22,083$43.59$962,597.97View SEC Filing  
6/2/2016Darren S ClineEVPSell3,366$42.07$141,607.62View SEC Filing  
5/27/2016Clay B SiegallCEOSell48,660$40.41$1,966,350.60View SEC Filing  
5/24/2016Clay B SiegallCEOSell8,400$40.09$336,756.00View SEC Filing  
5/23/2016Clay B SiegallCEOSell6,700$40.12$268,804.00View SEC Filing  
5/17/2016Clay B SiegallCEOSell7,618$35.16$267,848.88View SEC Filing  
4/25/2016Clay B SiegallCEOSell800$40.00$32,000.00View SEC Filing  
4/5/2016Clay B SiegallCEOSell7,618$36.12$275,162.16View SEC Filing  
3/22/2016Clay B SiegallCEOSell15,236$35.52$541,182.72View SEC Filing  
3/21/2016Clay B SiegallCEOSell4,282$35.01$149,912.82View SEC Filing  
3/17/2016Felix BakerDirectorBuy124,065$31.85$3,951,470.25View SEC Filing  
3/16/2016Felix BakerDirectorBuy1,349,237$32.10$43,310,507.70View SEC Filing  
3/15/2016Felix BakerDirectorBuy661,093$32.08$21,207,863.44View SEC Filing  
3/14/2016Felix BakerDirectorBuy118,941$33.77$4,016,637.57View SEC Filing  
3/11/2016Felix BakerDirectorBuy694,666$32.46$22,548,858.36View SEC Filing  
3/8/2016Felix BakerDirectorBuy502,523$22.66$11,387,171.18View SEC Filing  
3/2/2016Felix BakerDirectorBuy675,922$31.77$21,474,041.94View SEC Filing  
3/1/2016Felix BakerDirectorBuy24,200$31.24$756,008.00View SEC Filing  
2/29/2016Felix BakerDirectorBuy251,722$30.39$7,649,831.58View SEC Filing  
2/26/2016Felix BakerDirectorBuy314,508$29.55$9,293,711.40View SEC Filing  
2/22/2016Felix BakerDirectorBuy1,001,471$29.63$29,673,585.73View SEC Filing  
2/17/2016Felix BakerDirectorBuy1,269,147$30.43$38,620,143.21View SEC Filing  
2/12/2016John A. OrwinDirectorBuy2,000$28.33$56,660.00View SEC Filing  
12/15/2015Vaughn B. HimesEVPSell40,500$39.94$1,617,570.00View SEC Filing  
12/3/2015Clay B. SiegallCEOSell3,720$39.99$148,762.80View SEC Filing  
11/20/2015Felix BakerDirectorBuy329,358$43.94$14,471,990.52View SEC Filing  
11/17/2015Clay B SiegallCEOSell87,473$45.40$3,971,274.20View SEC Filing  
11/11/2015Darren S ClineSVPSell5,769$45.68$263,527.92View SEC Filing  
11/10/2015Felix BakerDirectorBuy934,624$42.95$40,142,100.80View SEC Filing  
11/9/2015Felix BakerDirectorBuy507,300$43.76$22,199,448.00View SEC Filing  
11/6/2015Eric DobmeierCOOSell17,452$42.50$741,710.00View SEC Filing  
11/6/2015Felix BakerDirectorBuy417,924$41.94$17,527,732.56View SEC Filing  
11/5/2015David W GryskaDirectorSell10,000$43.57$435,700.00View SEC Filing  
11/4/2015Clay B. SiegallCEOSell3,718$43.14$160,394.52View SEC Filing  
10/5/2015Clay B. SiegallCEOSell3,718$41.30$153,553.40View SEC Filing  
9/3/2015Clay B. SiegallCEOSell3,718$40.12$149,166.16View SEC Filing  
8/20/2015Clay B. SiegallCEOSell31,754$42.02$1,334,303.08View SEC Filing  
8/20/2015Darren S. ClineSVPSell2,231$42.02$93,746.62View SEC Filing  
8/20/2015Eric DobmeierCOOSell8,548$42.02$359,186.96View SEC Filing  
8/20/2015Jonathan G. DrachmanCMOSell4,462$42.02$187,493.24View SEC Filing  
8/20/2015Todd E. SimpsonCFOSell5,825$42.02$244,766.50View SEC Filing  
8/20/2015Vaughn B. HimesEVPSell5,997$42.02$251,993.94View SEC Filing  
7/6/2015Clay B SiegallCEOSell3,718$46.94$174,522.92View SEC Filing  
6/3/2015Clay B SiegallCEOSell3,718$45.72$169,986.96View SEC Filing  
5/21/2015Felix BakerDirectorBuy950,886$42.49$40,403,146.14View SEC Filing  
5/8/2015Eric DobmeierCOOSell17,074$40.38$689,448.12View SEC Filing  
5/7/2015Felix BakerDirectorBuy1,032,664$35.56$36,721,531.84View SEC Filing  
3/10/2015Felix BakerDirectorBuy285,036$34.66$9,879,347.76View SEC Filing  
3/9/2015Felix BakerDirectorBuy275,717$34.66$9,556,351.22View SEC Filing  
3/4/2015Felix BakerDirectorBuy448,841$34.84$15,637,620.44View SEC Filing  
2/25/2015Felix BakerDirectorBuy281,115$33.92$9,535,420.80View SEC Filing  
1/6/2015Clay B SiegallCEOSell16,804$31.80$534,367.20View SEC Filing  
12/16/2014Felix BakerDirectorBuy2,883,378$31.86$91,864,423.08View SEC Filing  
12/10/2014Felix BakerDirectorBuy1,247,896$33.82$42,203,842.72View SEC Filing  
12/9/2014Felix BakerDirectorBuy128,430$34.16$4,387,168.80View SEC Filing  
12/8/2014Felix BakerDirectorBuy465,316$32.93$15,322,855.88View SEC Filing  
11/12/2014Vaughn B HimesEVPSell10,000$37.52$375,200.00View SEC Filing  
11/10/2014Felix BakerDirectorBuy1,653,925$34.56$57,159,648.00View SEC Filing  
9/4/2014Clay B SiegallCEOSell5,600$42.54$238,224.00View SEC Filing  
8/12/2014Clay B SiegallCEOSell11,200$40.38$452,256.00View SEC Filing  
8/11/2014Clay B SiegallCEOSell2,700$40.05$108,135.00View SEC Filing  
6/13/2014Felix BakerDirectorBuy216,595$39.92$8,646,472.40View SEC Filing  
6/10/2014Clay B SiegallCEOSell11,200$40.14$449,568.00View SEC Filing  
6/9/2014Felix BakerDirectorBuy546,252$38.16$20,844,976.32View SEC Filing  
6/4/2014Felix BakerDirectorBuy281,963$34.86$9,829,230.18View SEC Filing  
5/16/2014Felix BakerDirectorBuy189,611$34.07$6,460,046.77View SEC Filing  
4/3/2014Clay SiegallCEOSell5,600$43.34$242,704.00View SEC Filing  
2/18/2014Clay SiegallCEOSell100,000$51.97$5,197,000.00View SEC Filing  
1/21/2014Eric DobmeierCOOSell56,010$47.92$2,683,999.20View SEC Filing  
1/16/2014Jonathan DrachmanCMOSell1,201$45.75$54,945.75View SEC Filing  
12/16/2013Felix BakerDirectorBuy407,078$39.66$16,144,713.48View SEC Filing  
12/5/2013Felix BakerDirectorBuy1,005,901$43.19$43,444,864.19View SEC Filing  
10/1/2013Clay B SiegallCEOSell2,000$43.87$87,740.00View SEC Filing  
9/10/2013Eric DobmeierCOOSell42,000$46.40$1,948,800.00View SEC Filing  
9/5/2013Eric DobmeierCOOSell75,000$42.64$3,198,000.00View SEC Filing  
9/3/2013Clay B SiegallCEOSell102,000$43.90$4,477,800.00View SEC Filing  
9/3/2013David W GryskaDirectorSell10,000$42.48$424,800.00View SEC Filing  
8/27/2013Todd SimpsonCFOSell37,763$41.45$1,565,276.35View SEC Filing  
8/19/2013Clay SiegallCEOSell7,653$40.91$313,084.23View SEC Filing  
8/19/2013Eric DobmeierCOOSell3,328$40.91$136,148.48View SEC Filing  
8/19/2013Vaughn HimesEVPSell1,736$40.91$71,019.76View SEC Filing  
8/1/2013Clay B SiegallCEOSell2,000$40.03$80,060.00View SEC Filing  
7/12/2013Todd E SimpsonCFOSell92,527$37.45$3,465,136.15View SEC Filing  
7/1/2013Clay B SiegallCEOSell2,000$32.59$65,180.00View SEC Filing  
6/14/2013Srinivas AkkarajuDirectorSell5,000$32.75$163,750.00View SEC Filing  
6/13/2013Vaughn B HimesEVPSell10,000$32.11$321,100.00View SEC Filing  
6/3/2013Clay B SiegallCEOSell2,000$33.88$67,760.00View SEC Filing  
5/10/2013Srinivas AkkarajuDirectorSell17,500$37.17$650,475.00View SEC Filing  
3/6/2013Eric DobmeierCOOSell100,000$29.68$2,968,000.00View SEC Filing  
2/25/2013David W GryskaDirectorSell10,000$27.17$271,700.00View SEC Filing  
2/1/2013Clay B SiegallCEOSell2,000$29.61$59,220.00View SEC Filing  
1/15/2013Thomas C ReynoldsInsiderSell125,079$28.00$3,502,212.00View SEC Filing  
11/1/2012Clay B SiegallCEOSell8,250$25.51$210,457.50View SEC Filing  
9/4/2012Clay B SiegallCEOSell8,250$26.54$218,955.00View SEC Filing  
(Data available from 1/1/2013 forward)


Headline Trends for Seattle Genetics (NASDAQ:SGEN)
Latest Headlines for Seattle Genetics (NASDAQ:SGEN)
DateHeadline logoForm 4 SEATTLE GENETICS INC For: May 19 Filed by: LIPPMAN MARC E - May 24 at 9:27 AM logoSeattle Genetics, Inc. (SGEN) Given Average Recommendation of "Hold" by Analysts - May 23 at 7:28 AM logoSeattle Genetics, Inc. (SGEN) Leads 10 Notable Investor Filings - - May 19 at 12:44 PM logoSeattle Genetics, Inc. breached its 50 day moving average in a Bullish Manner : SGEN-US : May 19, 2017 - May 19 at 12:44 PM logoSeattle Genetics, Inc. (SGEN) Leads 10 Notable Investor Filings - May 18 at 5:30 PM logoSeattle Genetics to Present at Bank of America Merrill Lynch 2017 Healthcare Conference - May 9 at 10:33 AM logoTheStreet Downgrades Seattle Genetics, Inc. (SGEN) to Sell - May 9 at 10:26 AM logoThe Head-Scratching Reason Immunomedics Rose by as Much as 12% - May 8 at 7:15 PM logoDid Immunomedics Rise Too Much as Seattle Genetics Deal ... - 24/7 Wall St. - May 7 at 8:28 AM logoBRIEF-Seattle Genetics terminates license agreement with Immunomedics - May 6 at 7:34 PM logoSeattle Genetics (SGEN) Terminates License Agreement with Immunomedics (IMMU) for Sacituzumab Govitecan ... - - May 6 at 1:07 AM logoSeattle Genetics (SGEN) Receiving Favorable News Coverage, Analysis Finds - May 6 at 12:52 AM logoZacks: Brokerages Expect Seattle Genetics, Inc. (SGEN) Will Announce Earnings of -$0.45 Per Share - May 5 at 11:45 PM logoSeattle Genetics Terminates License Deal With Immunomedics For IMMU-132 - May 5 at 8:05 PM logoSeattle Genetics ends $2B cancer drug deal with Immunomedics derailed by board fight - May 5 at 8:05 PM logoSeattle Genetics Terminates License Agreement with Immunomedics for Sacituzumab Govitecan (IMMU-132) - May 5 at 8:05 PM logoBiotech Movers: Immunomedics Shares Jump After License Pact with Seattle Genetics Is Terminated - May 5 at 8:05 PM logoSeattle Genetics COO: Will remain opportunistic - May 5 at 12:42 PM logoETFs with exposure to Seattle Genetics, Inc. : May 4, 2017 - May 4 at 8:05 PM logoZacks: Brokerages Anticipate Seattle Genetics, Inc. (SGEN) Will Post Quarterly Sales of $107.15 Million - May 4 at 12:28 PM logoSeattle Genetics, Inc. (SGEN) Receives Consensus Rating of "Hold" from Analysts - May 4 at 1:33 AM logoSeattle Genetics, Inc. :SGEN-US: Earnings Analysis: Q1, 2017 By the Numbers : May 3, 2017 - May 3 at 5:57 PM logoSeattle Genetics, Inc. breached its 50 day moving average in a Bearish Manner : SGEN-US : May 3, 2017 - May 3 at 10:57 AM logoSeattle Genetics (SGEN) Earning Somewhat Favorable Media Coverage, Study Shows - May 3 at 1:01 AM logoSeattle Genetics, Inc. (SGEN) Expected to Post Earnings of -$0.44 Per Share - May 2 at 3:54 PM logoSeattle Genetics, Inc. (SGEN) Rating Increased to Hold at Zacks Investment Research - May 2 at 1:56 PM logoSeattle Genetics, Inc. Earnings: Solid Quarter, but Investors Wait - May 1 at 2:19 PM logoSeattle Genetics (SGEN) PT Raised to $75 at HC Wainwright; ' Like Commercial Progress & Pipeline Diversification' - - April 30 at 1:12 AM logoSeattle Genetics (SGEN) Q1 Loss Widens, Sales Top Estimates - Yahoo Finance - April 30 at 1:12 AM logoSeattle Genetics, Inc. (SGEN) Announces Quarterly Earnings Results, Misses Estimates By $0.01 EPS - April 29 at 1:01 AM logoSeattle Genetics, Inc. (SGEN) Rating Reiterated by HC Wainwright - April 28 at 10:40 PM logoEdited Transcript of SGEN earnings conference call or presentation 27-Apr-17 8:30pm GMT - April 28 at 9:21 PM logoSeattle Genetics (SGEN) Receiving Somewhat Favorable News Coverage, Study Finds - April 28 at 6:50 PM logoEARNINGS SUMMARY: Details of Seattle Genetics Inc. Q1 Earnings Report - April 28 at 1:14 AM logoInvestor Network: Seattle Genetics, Inc. to Host Earnings Call - April 28 at 1:14 AM logoSeattle Genetics Reports First Quarter 2017 Financial Results - April 28 at 1:14 AM logoSeattle Genetics, Inc. (SGEN) Posts Earnings Results - April 28 at 1:03 AM logoCann Reaffirms "Hold" Rating for Seattle Genetics, Inc. (SGEN) - April 27 at 11:12 PM logoSeattle Genetics Reports First Quarter 2017 Financial Results - Yahoo Finance - April 27 at 8:13 PM logoSeattle Genetics reports 1Q loss - Yahoo Finance - April 27 at 8:13 PM logoSeattle Genetics reports 1Q loss - April 27 at 4:07 PM logoFour Biotech Picks Ahead of Earnings - Barron's - April 26 at 4:17 PM logoSeattle Genetics (SGEN) Receiving Somewhat Critical News Coverage, Study Shows - April 25 at 6:44 PM logoSeattle Genetics (SGEN) Given Media Sentiment Rating of 0.20 - April 22 at 3:13 PM logoWhy Immunomedics, Inc. Got Hammered Today - April 21 at 7:33 PM logoSomewhat Negative Press Coverage Very Likely to Impact Seattle Genetics (SGEN) Share Price - April 17 at 7:25 PM logoSeattle Genetics (SGEN) Receiving Somewhat Critical News Coverage, Analysis Shows - April 14 at 4:10 PM logoSeattle Genetics, Inc. breached its 50 day moving average in a Bullish Manner : SGEN-US : April 14, 2017 - April 14 at 12:38 PM logoZacks: Brokerages Anticipate Seattle Genetics, Inc. (SGEN) to Announce -$0.41 EPS - April 11 at 10:49 AM logoSeattle Genetics, Inc. (SGEN) Short Interest Update - April 10 at 9:50 PM



Seattle Genetics (SGEN) Chart for Thursday, May, 25, 2017

This page was last updated on 5/25/2017 by Staff